In issue 42 of Diabetes Care released on December 2019, Matthew C. Riddle wrote the article “A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm”. 1

Riddle points out that the cardiovascular safety of sulfonylureas has been debated for nearly 50 years. He notes that, now, two convincing comparisons showed the former “neither an increase nor a decrease of risk with linagliptin versus placebo”, the second “the lack of excess cardiovascular risk with glimepiride versus linagliptin”... Accedi per continuare la lettura

 11/02/2021   09/03/2021      Visite